BSG guidelines for the management of hepatocellular carcinoma (HCC) in adults

Published April 2024

Deaths from the majority of cancers are falling globally, but the incidence and mortality from hepatocellular carcinoma (HCC) is increasing in the United Kingdom and in other Western countries. HCC is a highly fatal cancer, often diagnosed late, with an incidence to mortality ratio that approaches 1. Despite there being a number of treatment options, including those associated with good medium to long-term survival, 5-year survival from HCC in the UK remains below 20%. Sex, ethnicity and deprivation are important demographics for the incidence of, and/or survival from, HCC. These clinical practice guidelines will provide evidence-based advice for the assessment and management of patients with HCC. The clinical and scientific data underpinning the recommendations we make are summarised in detail. Much of the content will have broad relevance, but the treatment algorithms are based on therapies that are available in the UK and have regulatory approval for use in the National Health Service.

Read More

BSG logo
EUropean consensus on the Resolution Of SympToms After oesophago-gastric Resection (EUROSTAR): Peri-Operative Quality Initiative (POQI) consensus statement
clinical-resource/EUropean-consensus-Resolution-Of-SympToms

BSG logo
Position Statements
Neurogastroenterology and Motility
Small Bowel and Nutrition
New framework to support critical care clinicians in the care of people with severe eating disorders in life threatening situations who are referred to critical care via mental health services
clinical-resource/Framework-life-threatening-eating-disorders